Drug and Therapy Development for Triple Negative Breast Cancer - Hardcover

 
9783527351756: Drug and Therapy Development for Triple Negative Breast Cancer

Inhaltsangabe

A holistic view on TNBC that integrates the latest advances in the etiology, detection, diagnosis and treatment of this agressive cancer, laying the ground for the development of novel therapies.

Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.

Über die Autorin bzw. den Autor

Dr. Pravin Kendrekar, School of Natural Sciences, University of Central Lancashire, Preston, UK.
 
Dr. Vinayak Adimule, Angadi Institute of Technology and Management, Belagavi, India.
 
Dr. Tara Hurst, Pandemic Sciences Institute, University of Oxford, Oxford, UK.

Von der hinteren Coverseite

The first comprehensive and up-to-date compilation of modern diagnostic and treatment methods for triple negative breast cancer

In Drug and Therapy Development for Triple Negative Breast Cancer, a team of distinguished practitioners delivers an in-depth and authoritative discussion of contemporary methods for treating triple negative breast cancer (TNBC). The editors have included material that covers its molecular causes, initial detection, diagnostic tools, treatment procedures, pharmacology, and new and experimental therapies―including nanotherapeutics and photothermal therapies.

As the first comprehensive compilation of modern treatment methods for TNBC, this reference is an unmatched source of information about current and future treatment approaches, including machine learning methods for earlier detection and more accurate diagnosis. Readers will also find:

  • A thorough introduction to HER receptors in breast cancers
  • Comprehensive explorations of the etiology and therapy of hormone receptor-positive breast cancer and the early-stage diagnosis of breast cancer
  • Application of artificial intelligence to breast cancer diagnosis
  • New insights on the role of DNA replication stress and genome instability in breast cancer

Perfect for medicinal and pharmaceutical chemists, Drug and Therapy Development for Triple Negative Breast Cancer will also benefit oncologists and professionals working in the pharmaceutical industry or in hospital settings.

„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.